Perlong Medical rides on robust economic strength

Updated on 13 August 2012

How strong is your presence in the medical equipment sector in China?
Perlong Medical is a leading manufacturer in China. We have been at the forefront of medical equipment manufacturing since the very beginning. We attribute our strong presence to our robust economic strength and our early venture in the domain of medical manufacturing.

What is the organizational structure of the company?
Perlong Medical is presently a Joint Stock Group. We are yet to go public in China. We currently employ more than 1,500 people.

Do you have any plans of expansion?
Perlong Medical presently has one corporate facility. However, we have a substantial set up for R&D. We have several research projects in our pipeline, some of which are also in the field of general technology. Furthermore, our current plans from the point-of-view of expansion is to obtain more patents in the field of medical equipment technology.

What are the company's significant milestones and achievements?
Following our establishment in 1993, Perlong Medical launched its first series of products, including ESR-analyzer and blood coagulation analyzer in 1996. We introduced our hematology analyzer and hematology reagents in 2002 following which we launched our first product of x-ray series PLX102 in 2003. This year also saw the launch of our SARS equipment. In 2005, we obtain the ISO 9000 and ISO 13485 certifications.

The year 2008, saw our earthquake machine get the affirmation from the Chinese government. We were also conferred the national award of High Technology Enterprise in 2008. In 2009, three of our products, including PLX112C. PLX8200, PLX8200A obtained the High Technology Products award from the Government of China. Particularly, our product PLX8200, which is a high frequency digital radiography system, won the Independent and Innovation Products (national award). We also obtained four patents and five soft copyrights for our creations in 2009. In 2010, we were awarded the municipal award of Annual Innovational Brand.

Previous 1 2

Leave a Reply

Notify me of follow-up comments via e-mail address

Post Comment

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X